Marc DE GARIDEL
President, European Biopharmaceuticals Enterprises (EBE),
Chairman and Chief Executive Officer, Ipsen
Marc de Garidel is Chairman and Chief Executive Officer of Ipsen Group, a global biopharmaceutical Group.
Prior to this position, Marc de Garidel was a vice-president of Amgen International, responsible for the South Region. His region includes Southern Europe territories, Turkey, Middle-East, Africa, & South America. Prior to that assignment, he was in charge of the Southwest region in 2006 & of the French affiliate between 2000 & 2005. Marc de Garidel built in that period the largest affiliate outside of the US.
He started with Amgen in 1995 as VP Finance Europe & became Corporate Controller of Amgen Inc in 1998.
Marc de Garidel gained his first professional experience with Eli Lilly working in several functions & in different countries such as the US, Germany & France.
Marc de Garidel is a graduate of the Executive MBA at Harvard Business School (AMP), has Master's Degree in International Management & Master's in Civil Engineering.
Besides his current responsibilities, he is President of EBE (European Biopharmaceutical Entreprises) since June 2010 and member of the Board of EFPIA, European Federation of Pharmaceutical Industries and Associations. He has been a founder & president of the French LEEM Biotech Association between 2004 & 2006. Since January 2011, Marc de Garidel is Chairman and Spokesman of the G5, an association of French companies specialized in health and life sciences (bioMérieux, Ipsen, LFB, Pierre Fabre, sanofi-aventis and Servier are companies whose decision-making centres are based in France, are internationally competitive and make research efforts a high priority).
He is also Chairman of the Board of Promothera Bioscience, a cell therapy start-up in Belgium. He is also Member of the Board of TCland Expression & Protein'Therapeutics.
Marc de Garidel is also Chevalier de la Légion d'Honneur & is a co-author of a book called « La Société du Médicament » published in 2006."